VivoSeq
Other

Surufatinib

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Surufatinib is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

11/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed4 · 44%
Recruiting1 · 11%
Not yet recruiting1 · 11%
Unknown status1 · 11%
No longer available1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Recruiting·PPeking University·Phase 2·NCT05165407·30 enrolled
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06375642·30 enrolled
A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
Completed·HHutchison Medipharma Limited·Phase 1·NCT04372394·28 enrolled
A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
Completed·HHutchison Medipharma Limited·Phase 1·NCT04372407·13 enrolled
Surufatinib DDI With a PPI and a CYP3A Inducer
Completed·HHutchison Medipharma Limited·Phase 1·NCT04510649·28 enrolled
Open-label Study of Surufatinib in Japanese Patients
Completed·HHutchmed·Phase 1/2·NCT05077384·36 enrolled
Open-Label Surufatinib in European Patients With NET
Terminated·HHutchmed·Phase 2·NCT04579679·78 enrolled
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Unknown status·—·Phase 2·NCT05668767·20 enrolled
Expanded Access Program of Surufatinib
No longer available·HHutchmed·N/A·NCT04814732

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)